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Abstract 
We present a case of necrobiosis lipoidica (NL) with atypical early lesions and good 
response to topical tacrolimus. NL is a disease with clinical features that are seldom 
misinterpreted. Often histology just confirms the clinician’s diagnosis. Only in rare cases, 
the clinical presentation and the involved body sites may be misleading. A 67-year-old 
diabetic woman was admitted to our department with a well-defined, persistent plaque 
on her left arm and on her right shin. Histologic examination of both lesions revealed 
features of NL despite the dissimilar clinical presentation. The patient was treated with 
0.1% topical tacrolimus ointment twice daily for 8 weeks and once daily for 8 weeks. A 
significant improvement and no further lesions were observed after 1 year of follow-up. 
A high index of suspicion regarding NL lesions with atypical clinical presentation on 
different body sites is advised in order to avoid misdiagnosis, wrong treatment decisions 
and ulceration. Additionally, it appears that topical tacrolimus treatment is an effective 
therapeutic option in patients with recent, non-ulcerated NL lesions.  
 
Introduction 
Necrobiosis lipoidica (NL) is a disease with clinical features that are seldom 
misinterpreted. Often histology just confirms the clinician’s diagnosis. Only in rare cases, 
the clinical presentation and the involved body sites may be misleading. 
Case Report 
A 67-year-old woman was admitted to our department with a well-defined, persistent plaque on her 
right shin (fig. 1) and on her left arm (fig. 2). The old lesion, which was located on the anterior surface 
of the shin, was characterized by sharply defined, slightly elevated, red-bluish borders and a yellow-
orange, atrophic, porcelain-like center. The recent lesion presented as an erythematous plaque on the  
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left arm. Both lesions were not painful, but slightly pruritic and there was no history of recent trauma or 
infection. The patient had a history of type 2 diabetes mellitus (DM) since 2000. Blood glucose levels 
had been poorly controlled ever since, with HbA1C reaching 7.3%, but with no apparent complications 
of DM. The chest X-ray was completely normal. Although clinically the shin lesion was compatible with 
NL, the arm lesion was not typical of any dermatosis. Therefore, both lesions were biopsied to identify 
their nature and rule out sarcoidosis or granuloma annulare. Histology revealed identical features 
despite the dissimilar clinical presentation. A granulomatous dermatitis with foci of degenerated 
collagen surrounded by histiocytes, some of them multinucleated (fig. 3), as well as thickened collagen 
bundles arranged horizontally in the dermis are all typical findings of NL. The patient was treated with 
0.1% topical tacrolimus ointment twice daily for 8 weeks and once daily for 8 weeks. A significant 
improvement and no further lesions were observed after 1 year of follow-up. 
Discussion 
NL is a granulomatous skin disease of unknown etiology, associated mainly with DM. 
It more commonly occurs in women than in men with a ratio of 3:1 [1–3]. The average 
age of onset is 30–40 years [1–3], although it has been frequently reported in older age 
groups and seldom in children [2]. The lesions are distributed on the anterior and lateral 
surfaces of the lower legs. However, there are other sites that can rarely be affected, such 
as upper extremities [1, 2], trunk [1, 3], face (even periorbitally), scalp [1, 3] and penis [3, 
4]. 
The pathogenesis of NL remains unclear. However, diabetic microangiopathy, 
immune-complex vasculitis, and collagen abnormalities are some potential underlying 
causes [1]. Nakajima et al. [5] assert that both hyperlipidemia and venous reflux, in 
addition to other pathogenic factors, can trigger tissue damage in the lower legs and lead 
to the onset of NL. In constrast, Ngo et al. [6] refute the hypothesis that NL is a 
manifestation of microvascular ischemic disease of the skin and conclude that the 
increased blood flow seen in NL lesions suggests an ongoing inflammatory process.  
Despite the debates on pathogenesis, the association between DM and NL remains a 
fact. 75–90% of patients with NL have or will develop DM [2, 3]. Therefore, NL is 
considered to be a dermatologic marker for DM [2]. In contrast, NL is present only in 
0.3–3% of the diabetic population [1–3]. It is most commonly seen in patients with type 1 
DM, but may also occur in type 2 DM [7]. Whether glucose control and treatment of DM 
improve or have no effect on NL lesions is still a controversy [1, 2]. NL has also been 
associated with other diseases such as sarcoidosis, rheumatoid arthritis, autoimmune 
thyroid disease and inflammatory bowel disease [3]. 
NL presents spontaneous remission in less than 20% of cases [1]. Ulceration is the 
most frequent and hard to treat complication of NL in 25–33% of patients [1–3]. 
Additionally, squamous cell carcinoma developing in areas of NL has also been reported 
[1–3]. 
Although there are plenty therapeutic options for NL, its treatment is still challenging 
and sometimes ineffective [1, 2]. First-line treatment includes corticosteroids, either 
topically or intralesionally, and sometimes systemically [1–3, 8]. According to some 
reports, smoking cessation and blood glucose control is recommended [1, 2]. Other 
therapeutic options are antiplatelet agents [3], cyclosporine [1–3, 8], thalidomide [3, 8], 
clofazimine [2], anti-TNF agents [3, 8], fumaric acid esters [2, 8], PUVA [2, 3, 8], 
photodynamic therapy [8, 9], hydroxychloroquine [10] and tacrolimus [3, 11–13].  
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We report a case of non-ulcerated, recent lesions of NL well managed with topical 
tacrolimus 0.1% ointment twice daily for 8 weeks and once daily for 8 weeks. Despite the 
limited experience with topical tacrolimus treatment in NL, the few existing references 
seem quite encouraging (table 1). Tacrolimus induces anti-inflammatory and 
immunomodulatory effects with suppression of the granulomatous infiltrate in 
granuloma annulare and NL, including the reduction of chemotactic activity of fibroblasts 
and the inhibition of collagen synthesis [11–13]. Subsequently, tacrolimus is thought to be 
effective at the early inflammatory stages of NL.  
Making a diagnosis of NL of the lower legs is not difficult; however, a high index of 
suspicion regarding NL lesions with atypical clinical presentation on different body sites 
is advised in order to avoid misdiagnosis, wrong treatment decisions and ulceration. 
Additionally, it appears that topical tacrolimus treatment is an effective therapeutic 
option in patients with recent, non-ulcerated NL lesions. 
Disclosure Statement 
The authors have no conflict of interest to declare. 
 
 
 
Table 1. Use of 0.1% topical tacrolimus ointment in NL 
First author  Number of 
patients 
Treatment Outcome 
Barth [12]  1  12 weeks  Improvement
Clayton [11]  1  01 month  Improvement
Harth [13]  2  08 weeks  Improvement
 
 
 
 
 
Fig. 1. Lesion on the right shin. 
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Fig. 2. Lesion on the left arm. 
 
 
 
Fig. 3. Foci of degenerated collagen surrounded by histiocytes; some of them were multinucleated; HE 
× 40. 
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